Vaptan15 mg

Vaptan is a selective vasopressin V2-receptor antagonist (aquaretic) approved for two distinct clinical uses, each with its own dosing range and safety program:

Established, FDA-approved uses

• Clinically significant hypervolemic and euvolemic hyponatremia, including hyponatremia associated with heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Vaptan is used to raise serum sodium concentration in patients with a serum sodium below 125 mEq/L, or with less severe hyponatremia that is symptomatic and has resisted fluid restriction.
• Slowing the decline in kidney function in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD), used at a specifically-approved, higher-dose titration regimen distinct from the hyponatremia indication.

Not indicated / off-label caution

Vaptan is not indicated for hypovolemic hyponatremia or for situations requiring urgent correction of serum sodium. It is not a first-line diuretic for volume overload and is not interchangeable across its two approved indications without physician-directed, indication-specific dosing.

Each film-coated oral tablet contains Tolvaptan as the active ingredient, commonly available in strengths such as 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg (exact strengths and combination packs vary by manufacturer/market), along with standard pharmaceutical excipients.

Vaptan is a selective, orally active antagonist of the vasopressin V2 receptor found in the renal collecting ducts. By blocking the antidiuretic action of arginine vasopressin, Vaptan promotes excretion of electrolyte-free water (aquaresis) without a proportional loss of sodium and potassium, which helps correct dilutional hyponatremia. At the higher, specifically titrated doses used in autosomal dominant polycystic kidney disease (ADPKD), Vaptan also reduces cyclic AMP signaling implicated in renal cyst growth, helping to slow the decline in kidney function.

Vaptan carries a boxed warning: initiation and re-initiation for the hyponatremia indication must occur in a hospital setting with frequent serum sodium monitoring because of the risk of too-rapid sodium correction, and the higher-dose ADPKD regimen carries its own boxed warning for serious, potentially irreversible liver injury requiring a structured monitoring program.

Vasopressin V2-receptor antagonist (aquaretic agent) — Vaptan is the prototype drug of this class.

Mechanism

Tolvaptan selectively and competitively antagonizes vasopressin V2 receptors on the basolateral membrane of renal collecting-duct cells. This blocks vasopressin-mediated insertion of aquaporin-2 water channels, reducing water reabsorption and producing aquaresis (excretion of free water with minimal effect on electrolyte excretion). The result is a rise in serum sodium concentration and a reduction in total body water without significant natriuresis.

In ADPKD, V2-receptor blockade by Tolvaptan also lowers intracellular cyclic AMP in renal tubular and cystic epithelial cells, a pathway implicated in cyst cell proliferation and fluid secretion, which underlies its effect of slowing kidney volume growth and function decline.

Pharmacokinetics

Tolvaptan is absorbed orally with peak plasma concentration reached in about 2-4 hours; it is highly protein bound and extensively metabolized in the liver mainly via CYP3A4, with a plasma elimination half-life of roughly 6-8 hours. It is excreted predominantly via the biliary/fecal route, with minimal unchanged renal excretion.

Vaptan tablets are taken orally, once daily in the morning for the hyponatremia indication (to allow monitoring of the effects of aquaresis during waking hours), with or without food. For the ADPKD indication, Vaptan is taken as two doses daily — on waking and again about 8-9 hours later, roughly with meals, following a fixed physician-directed schedule.

Patients should have access to water and should drink in response to thirst; fluid should not be restricted during Vaptan initiation or titration unless specifically instructed. Missed doses should not be doubled up; contact the prescribing physician for guidance. Do not stop, skip, or change the Vaptan dose without medical advice, given the structured monitoring these regimens require.

Vaptan is metabolized mainly via CYP3A4, making it prone to clinically significant interactions:

• Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir): substantially increase Vaptan plasma levels, raising risk of excessive aquaresis and adverse effects; concomitant use is contraindicated.
• Moderate CYP3A4 inhibitors (e.g. diltiazem, fluconazole): increase Vaptan exposure — a lower starting dose and closer monitoring are generally required.
• Strong CYP3A4 inducers (e.g. rifampin, carbamazepine, St. John's Wort): reduce Vaptan plasma levels and may blunt its effect; higher doses may be needed and response should be monitored.
• Other vasopressin V2-receptor antagonists: concomitant use is contraindicated due to additive/overlapping effect.
• Hypertonic saline: should not be used concomitantly with Vaptan for correcting hyponatremia, as the combination can produce too-rapid sodium correction.
• Diuretics: concurrent use may increase risk of dehydration and hypovolemia; volume status should be monitored closely.

The most common adverse effects of Vaptan relate directly to its aquaretic mechanism:

• Very common: thirst, dry mouth, increased urination (polyuria), frequent urination (pollakiuria), nocturia.
• Common: fatigue/weakness (asthenia), constipation, dizziness, hyperglycemia, dry skin, decreased appetite, elevated liver enzymes.
• Serious (see Precautions): too-rapid correction of serum sodium leading to osmotic demyelination syndrome, serious liver injury, dehydration/hypovolemia, gastrointestinal bleeding (reported in ADPKD trials).

Patients should report unusual fatigue, jaundice, dark urine, severe nausea/vomiting, confusion, difficulty speaking or swallowing, or excessive thirst/urination promptly to their physician.

Pregnancy: Data on Vaptan use in pregnant women are limited. Animal studies have shown adverse effects on fetal development at high doses. Vaptan should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; use should be under close physician supervision.

Lactation: It is not known whether Vaptan passes into human breast milk. Because of the potential for aquaretic effects and electrolyte disturbance in a nursing infant, a decision should be made by the physician whether to discontinue breastfeeding or discontinue Vaptan, taking into account the importance of treatment to the mother. Consult a physician before use while breastfeeding.

Boxed warnings

• Osmotic demyelination risk (hyponatremia indication): Vaptan must be initiated and re-initiated in a hospital setting where serum sodium can be monitored closely, because too-rapid correction of hyponatremia (more than about 12 mEq/L in 24 hours) can cause osmotic demyelination syndrome, resulting in serious, potentially irreversible neurologic injury (dysarthria, mutism, dysphagia, lethargy, seizures). Risk is higher in patients with severe hyponatremia, malnutrition, alcoholism, or advanced liver disease.
• Serious liver injury (ADPKD indication, higher-dose regimen): Vaptan at ADPKD doses has been associated with serious, potentially fatal liver injury, including cases requiring transplant. Baseline and periodic liver function testing (per a structured monitoring program) is mandatory, with specific dose-interruption or discontinuation rules if transaminases or bilirubin rise beyond defined thresholds, or if symptoms of liver injury occur.

Other precautions

• Dehydration/hypovolemia: can occur due to the aquaretic effect; ensure patients have access to water and monitor volume status and renal function, especially in the elderly or those with limited mobility or altered thirst sensation.
• Thirst and dry mouth are very common due to the aquaretic mechanism and are expected, not a sign of overdose, unless severe.
• Hepatic impairment: requires caution and enhanced monitoring for the hyponatremia indication, and is contraindicated for ADPKD dosing above defined severity thresholds (see Contraindications).
• Drug interactions: significant interactions with CYP3A4 inhibitors/inducers require dose adjustment or avoidance (see Interactions).

Overdose with Vaptan may cause excessive aquaresis leading to dehydration, hypovolemia, and dangerously elevated serum sodium. There is no specific antidote. If overdose of Vaptan is suspected, seek immediate medical attention or contact a poison control center or emergency services right away; do not attempt unsupervised home treatment. Management in a medical facility typically involves close monitoring of volume status, serum electrolytes, and vital signs, with supportive care as directed by a physician.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: No specific dose adjustment is established, but Vaptan's aquaretic effect depends on adequate residual kidney function, so response may be reduced in significant renal impairment; use with medical supervision.
• Hepatic impairment: Requires caution and closer monitoring for the hyponatremia indication; contraindicated above defined severity thresholds for the ADPKD indication (see Contraindications).
• Elderly: May be more susceptible to dehydration, hypovolemia, and falls related to dizziness; monitor closely, particularly for volume status and serum sodium.
• Pediatric patients: Safety and efficacy have not been established (see Pediatric Uses).

For hyponatremia, Vaptan is generally used for a limited course guided by serum sodium normalization and clinical response; continued use beyond 30 days is generally avoided, especially in patients with any hepatic impairment, due to liver injury risk. For ADPKD, Vaptan is used long-term/chronically to slow kidney function decline, with treatment duration and continued eligibility determined by the physician based on ongoing liver function monitoring and tolerability.

Vasopressin receptor antagonists; Aquaretics (Tolvaptan is the representative agent)

Tolvaptan selectively blocks vasopressin V2 receptors in the renal collecting ducts, preventing aquaporin-2-mediated water reabsorption and producing electrolyte-free water excretion (aquaresis), which raises serum sodium; at ADPKD-specific doses it also reduces cyclic AMP signaling linked to renal cyst growth.

C

Safety and efficacy of Vaptan in pediatric patients have not been established. Vaptan is not recommended for use in children.